# Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

> **NCT01703260** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Nonalcoholic Steatohapatitis

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Pioglitazone
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01703260
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Company decision; No safety or efficacy concerns (see detailed description)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703260, "Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01703260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*